Aquinox Pharmaceuticals (NASDAQ:AQXP) announced its quarterly earnings data on Wednesday. The company reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.71, MarketWatch Earnings reports. The company had revenue of $25.00 million during the quarter.
Aquinox Pharmaceuticals opened at $3.17 on Friday, according to MarketBeat.com. Aquinox Pharmaceuticals has a 12-month low of $1.96 and a 12-month high of $16.90. The company has a market cap of $72.17 million, a price-to-earnings ratio of -1.48 and a beta of -13.81.
Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aquinox Pharmaceuticals in a research report on Wednesday, June 27th. Guggenheim lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $26.00 price target for the company. in a research report on Wednesday, June 27th. Needham & Company LLC lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. ValuEngine lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 11th. Finally, Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, July 2nd. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Aquinox Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $20.80.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.
Read More: Leveraged Buyout (LBO)
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.